Skip to main content

Detail

Michela de Martino
Michela de Martino, Ph.D.

Department of Urology
Position: Associate Professor

T +43 1 40400 60510
michela.demartino@meduniwien.ac.at

Further Information

Research interests

The topic of my research is urologic oncology. My main aim is to identify genetic and molecular markers for the diagnosis and prognosis of urologic cancers.

Techniques, methods & infrastructure

I apply standard molecular biology techniques in order to purify nucleic acids from urine, blood and tumor tissues. DNA and RNA samples are subjected to downstream processes to identify genetic variations and to investigate the expression of certain genes. My research is supported by the newest technologies in the field of molecular biology and genetics ranging from next generation sequencing (NGS) to broad range of real-time PCR-based applications included gene expression arrays.

Selected publications

  1. de Martino M, Taus C, Lucca I, Hofbauer SL, Haitel A, Shariat SF, Klatte T. Association of human telomerase reverse transcriptase gene polymorphisms, serum levels, and telomere length with renal cell carcinoma risk and pathology. Mol Carcinog. 2016 Oct;55(10):1458-66.
  2. de Martino M, Lucca I, Mbeutcha A, Wiener HG, Haitel A, Susani M, Shariat SF, Klatte T. Carbonic anhydrase IX as a diagnostic urinary marker for urothelial bladder cancer. Eur Urol. 2015 Oct;68(4):552-4.
  3. de Martino M, Zhuang D, Klatte T, Rieken M, Roupret M, Xylinas E, Clozel T, Krzywinski M, Elemento O, Shariat SF. Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib. Cancer Biol Ther. 2014 Sep;15(9):1239-47.
  4. de Martino M, Hoetzenecker K, Ankersmit HJ, Roth GA, Haitel A, Waldert M, Klatte T. Serum 20S proteasome is elevated in patients with renal cell carcinoma and associated with poor prognosis. Br J Cancer. 2012 Feb 28;106(5):904-8.
  5. de Martino M, Klatte T, Haitel A, Marberger M. Serum cell-free DNA in renal cell carcinoma: a diagnostic and prognostic marker. Cancer. 2012 Jan 1;118(1):82-90.